Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 6/20 | 0.47 |
| ▸ | MAOA | P21397 | 8/20 | 0.45 |
| ▸ | MAOB | P27338 | 8/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20340627 | 0.94 | MCL1 (0.50) | MCL1MAOAMAOBACHEHASPIN | |
| SCHEMBL17517537 | 0.86 | MCL1 (0.47) | MCL1MAOAMAOBACHEGRIN1 | |
| SCHEMBL17102971 | 0.85 | MAOA (0.53) | MCL1MAOAMAOBACHETBXAS1 | |
| SCHEMBL17102969 | 0.84 | MAOA (0.51) | MCL1MAOAMAOBACHETBXAS1 | |
| SCHEMBL17122539 | 0.83 | MCL1 (0.47) | MCL1 | |
| SCHEMBL17517538 | 0.79 | MCL1 (0.40) | MCL1MAOAMAOBACHEHASPIN | |
| SCHEMBL28805497 | 0.79 | MCL1 (0.46) | MCL1MAOAMAOB | |
| SCHEMBL20340633 | 0.79 | MCL1 (0.50) | MCL1MAOAMAOBACHE | |
| SCHEMBL20340621 | 0.79 | MCL1 (0.52) | MCL1MAOAMAOBACHETBXAS1 | |
| SCHEMBL20340623 | 0.79 | MCL1 (0.47) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2018-07-03 | — | — | US | disclosed |
| US-20160039845-A1 | BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039845-A1 | BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | BRCA1, CA7, DCK | MCL1 205/4885MAOA 3499/4885MAOB 1253/4885 |
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | BRCA1, CA7, DCK | MCL1 209/4885MAOA 3791/4885MAOB 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.